Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01330043 · ClinicalTrials.gov registry record · Phase 4
Extended Treatment for Smoking Cessation
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 223
- Enrollment target
NCT01330043: Completed Phase 4 study, sponsored by Stanford University.
NCT01330043 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 223 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01330043, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 223 participants
- Enrollment target
Study Summary
Adult smokers (21-65) and adolescent smokers (18 - 21) years of age residing in Alameda and Santa Clara counties will serve as the target population for this study. A total of 400 smokers meeting eligibility criteria will be randomized. Treatment will include both open label and extended treatment phases. Randomization. Participants will be randomized to extended therapy or control conditions at baseline (prior to open label treatment) and the analysis will be intention-to-treat (ITT) to avoid the threat of selection bias. Primary hypothesis. Smokers randomized to receive CBT during extended treatment will have a higher prolonged abstinence rate (PA) at 52 week and 104 week follow-up than participants in the Supportive therapy Control treatment.
Interventions
- DRUG Varenicline
- DRUG Bupropion
- DRUG Nicotine patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01330043
The ClinicalTrials.gov registry entry for NCT01330043 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Varenicline is the first listed.
NCT01330043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01330043 about?
NCT01330043 is a clinical study titled "Extended Treatment for Smoking Cessation". Adult smokers (21-65) and adolescent smokers (18 - 21) years of age residing in Alameda and Santa Clara counties will serve as the target population for this study. A total of 400 smokers meeting eligibility criteria will be randomized. Treatment will include both open label and extended treatment p...
What is the current status of trial NCT01330043?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 223 participants. The study started on 2010-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01330043?
The interventions under investigation include: Varenicline (DRUG), Bupropion (DRUG), Nicotine patch (DRUG).
Who is sponsoring clinical trial NCT01330043?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.